Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Pharmacy Regulation topic
No spam. Unsubscribe anytime.
Committee rejects measure to restrict compounded GLP-1 drugs after members warn of unintended consequences
Summary
A proposed Mississippi Active Pharmaceutical Ingredient Quality Assurance Act to restrict compounded GLP‑1 drugs and require FDA-approved APIs failed in committee after members warned it could hinder local compounding for specialized needs and that the state Board of Pharmacy might already have enforcement tools.
The committee debated a bill aimed at curbing non–FDA‑approved GLP‑1 compounding and improving API traceability and testing; sponsor Senator Filenggain (transcript spelling variants) said the bill would make it illegal to sell compounded GLP‑1 doses unless the active pharmaceutical ingredients met FDA or USP standards and were produced in inspected facilities. "The intent of the legislation is to try to rein in what we have already seen a small amount of in our state," the sponsor said, describing outreach to the Board of Pharmacy.
Several members raised concerns that the bill's requirements could harm small compounding pharmacies that provide individualized medications (dermatology, OB‑GYN, severe allergies) and that the Board of Pharmacy may already have enforcement authority. Senator Parks warned the measure could penalize necessary specialty compounding, and Senator Hill noted local pharmacies serve patients with specific needs. After debate and amendments (including a reverse repealer), the committee substitute failed on a counted vote, 7 yeas to 9 nays.
